"VolitionRx Limited NYSE AMERICAN VNRX Volition today announced preliminary data from a prospective multicentered Proof of Concept Study of  men into the utility of Volitions Nu.Q assays to diagnose men with highgrade prostate cancer. Volition panel PSA alone     At  specificity the Volition panel of five assays including PSA identified  of highgrade prostate cancers that require treatment as defined by Gleason Score. This compares with just  identified by ProstateSpecific Antigen PSA alone. This is a very exciting outcome for us as we continue the development of our assays beyond colorectal cancer. The preliminary data from this study showed that Volitions panel of assays identified men with potentially lethal highgrade prostate cancer with much greater accuracy than PSA alone.  Based on this data we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with lowgrade tumors or no tumor. The next step is to confirm these statistically significant findings in independent larger clinical trials said Dr. Jake Micallef Chief Scientific Officer at Volition. Prostate cancer PCA is the second leading cause of cancer death in men in the U.S. after lung cancer. Currently PCA is diagnosed through medical history physical examination and by elevated levels of PSA in the blood. Men suspected of PCA are given a prostate biopsy to confirm the presence of cancer. However most men with elevated PSA levels referred for prostate biopsy either have no cancer or have lowgrade cancer which needs monitoring but not treatment.  In the Proof of Concept Study a blood sample was taken prospectively from men referred for prostate biopsy in three Belgian hospitals. The men were grouped by biopsy findings as having no cancer most of whom had elevated PSA levels lowgrade cancer or highgrade cancer. The samples were tested with a panel of five assays PSA two Nu.Q assays and two inflammatory biomarkers.  The assay results correlated with the Gleason Score which is one of the main predictors for aggressive PCA determined on biopsy. This suggests the assays may provide better risk stratification than that available using PSA tests for men with actual or suspected PCA leading to better patient management and fewer unnecessary biopsies. Commenting on the results Principal Investigator Professor Thierry Roumeguere Head of Urological Services Erasme Hospital Brussels Belgium said A noninvasive test to help in the risk stratification of men with suspected or actual prostate cancer will be a major step forward in the management of this disease. The correlation of the panel blood test results with Gleason Score shows great promise in this regard. We will further investigate the data in relation to disease stage as well as additional factors used for pretreatment risk stratification.   Cameron Reynolds Chief Executive Officer at Volition commented This small trial is important because it helps demonstrate once more the potential breadth of our technology. If these results are validated in larger trials they will present a potentially significant new market opportunity. Volitions research team is continuing to develop our Nu.Q assays and we aim to launch products  in . Dr. Gaetan Michel Chief Executive Officer of Volitions whollyowned subsidiary Belgian Volition SPRL commented We would like to thank the Walloon Region for their continued support of the company. The funding provided by the region has enabled this study and will support our continued research. The Gleason Score is a method used to grade prostate cancers based on how normal or abnormal the prostate biopsy cancer tissue appears under the microscope.  https  About Volition Volition is a multinational life sciences company focused on developing simple easy to use cost effective blood tests designed to help diagnose a range of cancers.  The tests are based on the technology platform of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid  an indication that disease is present. As cancer screening programs become more widespread Volitions products aim to help to diagnose a range of cancers quickly simply accurately and cost effectively.  Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life.   Volition intends to expand the application of its technology beyond cancer by exploring other disease applications.  The companys research and development activities are currently centered in Belgium with additional offices in London Texas and Singapore as it focuses on bringing its diagnostic products to market first in Europe then in the U.S. and ultimately worldwide. For more information about Volition visit Volitions website httpsvolitionrx.com or connect with us via Twitter httpstwitter.comvolitionrx  LinkedIn https  Facebook https  YouTube https The contents found at Volitions website address Twitter LinkedIn Facebook and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volitions website Twitter LinkedIn Facebook and YouTube are included in this document as inactive textual references only. MediaInvestor Contacts Louise Day Chief Marketing  Communications Officer mediarelationsvolitionrx.com mailtomediarelationsvolitionrx.com    Scott Powell Executive Vice President Investor Relations investorrelationsvolitionrx.com mailtoinvestorrelationsvolitionrx.com     Joseph Green Edison Advisors jgreenedisongroup.com mailtojgreenedisongroup.com     Safe Harbor Statement Statements in this press release may be forwardlooking statements within the meaning of Section A of the Securities Act of  as amended and Section E of the Securities Exchange Act of  as amended that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forwardlooking statements. Words such as expects anticipates intends plans aims targets believes seeks estimates optimizing potential goal suggests could would should may will and similar expressions identify forwardlooking statements. These forwardlooking statements relate to the effectiveness of Volitions bodilyfluidbased diagnostic tests as well as Volitions ability to develop and successfully commercialize such test platforms for early detection of cancer andor other disease applications. Volitions actual results may differ materially from those indicated in these forwardlooking statements due to numerous risks and uncertainties. For instance if Volition fails to develop and commercialize diagnostic products it may be unable to execute its plan of operations. Other risks and uncertainties include Volitions failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market a failure by the marketplace to accept the products in Volitions development pipeline or any other diagnostic products Volition might develop Volition will face fierce competition and Volitions intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change and other risks identified in Volitions most recent Annual Report on Form K and Quarterly Reports on Form Q as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations estimates and projections about Volitions business based in part on assumptions made by management. These statements are not guarantees of future performance and involve risks uncertainties and assumptions that are difficult to predict. Forwardlooking statements are made as of the date of this release and except as required by law Volition does not undertake an obligation to update its forwardlooking statements to reflect future events or circumstances. Nucleosomics NuQ Nu.QTM and Hypergenomics and their respective logos are trademarks andor service marks of VolitionRx Limited and its subsidiaries. All other trademarks service marks and trade names referred to in this press release are the property of their respective owners. Additionally unless otherwise specified all references to  refer to the legal currency of the United States of America. SOURCE VolitionRx Ltd Related Links httpsvolitionrx.com"